Effect of inflammatory bowel disease on absorption and disposition of prednisolone

The pharmacokinetics and bioavailability of prednisolone after doses of oral prednisone and intravenous prednisolone were determined in seven patients receiving corticosteroids for treatment of inflammatory bowel disease in active disease and remission. Prednisone absorption and conversion to the ac...

Full description

Saved in:
Bibliographic Details
Published inDigestive diseases and sciences Vol. 28; no. 2; p. 161
Main Authors Milsap, R L, George, D E, Szefler, S J, Murray, K A, Lebenthal, E, Jusko, W J
Format Journal Article
LanguageEnglish
Published United States 01.02.1983
Subjects
Adolescent
Adult
Biological Availability
Blood Proteins - metabolism
Child
Colitis, Ulcerative - metabolism
Crohn Disease - metabolism
Female
Humans
Intestinal Absorption
Kinetics
Male
Prednisolone - metabolism
Prednisone - metabolism
Protein Binding
Online AccessGet more information

Cover

More Information
Summary:The pharmacokinetics and bioavailability of prednisolone after doses of oral prednisone and intravenous prednisolone were determined in seven patients receiving corticosteroids for treatment of inflammatory bowel disease in active disease and remission. Prednisone absorption and conversion to the active form of prednisolone was complete in both disease phases. Pharmacokinetic parameters for total and free (unbound) prednisolone did not differ significantly between disease phases. Differences in protein binding were observed between active disease and remission with the fractional binding of prednisolone to plasma proteins decreased in active disease. This may be accounted for by decreased plasma albumin concentrations in active disease. Alpha 1-acid glycoprotein concentrations were significantly higher in active disease but did not contribute to the overall binding of prednisolone.
ISSN:0163-2116
DOI:10.1007/BF01315146